These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 19373965)

  • 21. Comment on Xue et al.: Alendronate treatment improves bone-pedicle screw interface fixation in posterior lateral spine fusion: an experimental study in a porcine model.
    Singh S; Singh V; Joshi A
    Int Orthop; 2010 Dec; 34(8):1359. PubMed ID: 20455062
    [No Abstract]   [Full Text] [Related]  

  • 22. More on atypical fractures of the femoral diaphysis.
    Lee P; Seibel MJ
    N Engl J Med; 2008 Jul; 359(3):317; author reply 317-8. PubMed ID: 18642421
    [No Abstract]   [Full Text] [Related]  

  • 23. Bone turnover in bone biopsies of patients with low-energy cortical fractures receiving bisphosphonates: a case series.
    Armamento-Villareal R; Napoli N; Diemer K; Watkins M; Civitelli R; Teitelbaum S; Novack D
    Calcif Tissue Int; 2009 Jul; 85(1):37-44. PubMed ID: 19548019
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antiresorptive agents and osteoclast apoptosis.
    Stern PH
    J Cell Biochem; 2007 Aug; 101(5):1087-96. PubMed ID: 17407157
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Bone fracture and the healing mechanisms. The effects of anti-resorptive agents on fracture healing].
    Mashiba T; Mori S
    Clin Calcium; 2009 May; 19(5):673-9. PubMed ID: 19398835
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prediction of bone density around orthopedic implants delivering bisphosphonate.
    Stadelmann VA; Terrier A; Gauthier O; Bouler JM; Pioletti DP
    J Biomech; 2009 Jun; 42(9):1206-11. PubMed ID: 19380139
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Osteoclast inhibitors: a multifaceted tool in the management of breast cancer.
    Morikawa A; Van Poznak C
    Oncology (Williston Park); 2015 Jan; 29(1):39-42. PubMed ID: 25595285
    [No Abstract]   [Full Text] [Related]  

  • 28. [Is high-dose, orally administered alendronate analgesic?].
    Wilke D
    Med Monatsschr Pharm; 2014 Dec; 37(12):459-60. PubMed ID: 25643452
    [No Abstract]   [Full Text] [Related]  

  • 29. Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial.
    Stoch SA; Saag KG; Greenwald M; Sebba AI; Cohen S; Verbruggen N; Giezek H; West J; Schnitzer TJ
    J Rheumatol; 2009 Aug; 36(8):1705-14. PubMed ID: 19487264
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bisphosphonate-induced osteonecrosis of the jaw: a medical enigma?
    Siddiqi A; Payne AG; Zafar S
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2009 Sep; 108(3):e1-8. PubMed ID: 19570696
    [TBL] [Abstract][Full Text] [Related]  

  • 31. More on reports of esophageal cancer with oral bisphosphonate use.
    Shaheen NJ
    N Engl J Med; 2009 Apr; 360(17):1790-1; author reply 1791-2. PubMed ID: 19391257
    [No Abstract]   [Full Text] [Related]  

  • 32. By the way, doctor. I'm 69 and have taking Fosamax for 10 years. My doctor has approved a "drug holiday," provided we use a CTX test to monitor my bones. Can you explain?
    Robb-Nicholson C
    Harv Womens Health Watch; 2009 May; 16(9):8. PubMed ID: 19554747
    [No Abstract]   [Full Text] [Related]  

  • 33. Novel hypotheses in the etiopathogenesis of bisphosphonate-related osteonecrosis of the jaws.
    Kyrgidis A
    J Oral Maxillofac Surg; 2009 Nov; 67(11):2554. PubMed ID: 19837341
    [No Abstract]   [Full Text] [Related]  

  • 34. Histologic and histomorphometric features of bisphosphonate-related osteonecrosis of the jaws: an analysis of 31 cases with confocal laser scanning microscopy.
    Favia G; Pilolli GP; Maiorano E
    Bone; 2009 Sep; 45(3):406-13. PubMed ID: 19450715
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increased risk for bisphosphonate-related osteonecrosis of the jaws in patients wearing dentures could be attributable to impaired mucosal cell wound healing.
    Kyrgidis A; Vahtsevanos K
    J Oral Maxillofac Surg; 2009 Jun; 67(6):1355-6. PubMed ID: 19446234
    [No Abstract]   [Full Text] [Related]  

  • 36. Inhibition of interleukin-6 receptor directly blocks osteoclast formation in vitro and in vivo.
    Axmann R; Böhm C; Krönke G; Zwerina J; Smolen J; Schett G
    Arthritis Rheum; 2009 Sep; 60(9):2747-56. PubMed ID: 19714627
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Atrial fibrillation during bisphosphonate therapy. side effects or coincidental finding?].
    Ringe JD
    MMW Fortschr Med; 2009 Mar; 151(10):7. PubMed ID: 19472655
    [No Abstract]   [Full Text] [Related]  

  • 38. Odanacatib: location and timing are everything.
    Khosla S
    J Bone Miner Res; 2012 Mar; 27(3):506-8. PubMed ID: 22354850
    [No Abstract]   [Full Text] [Related]  

  • 39. Bioavailability and bioequivalence of two oral formulations of alendronate sodium 70 mg: an open-label, randomized, two-period crossover comparison in healthy Korean adult male volunteers.
    Rhim SY; Park JH; Park YS; Lee MH; Kim DS; Shaw LM; Yang SC; Kang JS
    Clin Ther; 2009 May; 31(5):1037-45. PubMed ID: 19539104
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Osteonecrosis of the jaw and bisphosphonate use in breast cancer patients.
    Kyrgidis A; Triaridis S; Vahtsevanos K; Antoniades K
    Expert Rev Anticancer Ther; 2009 Aug; 9(8):1125-34. PubMed ID: 19671032
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.